Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.39 |
| ▸ | HTR2C | P28335 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20022865 | 0.80 | HTR2A (0.65) | HTR2AHTR2CALDH1A1MCL1HTR7 | |
| Hydrochloric Acid SCHEMBL31573860 | 0.79 | HTR2A (0.63) | HTR2AHTR2CMAPTHTR6HTT | |
| SCHEMBL30819803 | 0.79 | HTR2A (0.39) | HTR2AHTR2CALDH1A1MEN1KMT2A | |
| SCHEMBL31573855 | 0.77 | HTR2A (0.42) | HTR2AHTR2CALDH1A1MCL1MEN1 | |
| SCHEMBL30703022 | 0.76 | HTR2A (0.64) | HTR2AHTR2CALDH1A1LMNAHTR1A | |
| SCHEMBL18154550 | 0.76 | MCL1 (0.41) | HTR2AHTR2CALDH1A1MCL1NPC1 | |
| SCHEMBL5917403 | 0.75 | HTR2A (0.68) | HTR2AHTR2CMCL1MAPT | |
| SCHEMBL20257503 | 0.75 | HTR2A (0.40) | HTR2AHTR2CHTR7LMNASMN1; SMN2 | |
| SCHEMBL4048826 | 0.75 | HTR2A (0.62) | HTR2AHTR2CALDH1A1MEN1KMT2A | |
| SCHEMBL20022863 | 0.75 | HTR2A (0.40) | HTR2AHTR2CMCL1PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117069726-A | Synthesis method of [1,2-a ] indole polycyclic derivative | 兰州大学 | 2023-11-17 | — | — | CN | disclosed |
| EP-1347979-B1 | INDOLE DERIVATIVES AND THEIR USE AS 5-HT2B AND 5-HT2C RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2007-08-08 | — | — | EP | disclosed |
| EP-1347979-A1 | INDOLE DERIVATIVES AND THEIR USE AS 5-HT2B AND 5-HT2C RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-01 | — | — | EP | disclosed |
| US-6610685-B2 | (S)-2-(6-ethoxy-2,3-dihydro-1H-3a-aza-cyclopenta(a)inden-8-yl)-1-methyl-ethylamine for example; treating diabetes; in combination with a lipase inhibitor such as orlistat | HOFFMANN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020160997-A1 | (S)-2-(6-ethoxy-2,3-dihydro-1H-3a-aza-cyclopenta(a)inden-8-yl)-1-methyl-ethylamine for example; treating diabetes; in combination with a lipase inhibitor such as orlistat | F.HOFFANN-LA ROCHE AG (CH) | 2002-10-31 | — | — | US | disclosed |
| WO-2002051844-A1 | INDOLE DERIVATIVES AND THEIR USE AS 5-HT2B AND 5-HT2C RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160997-A1 | (S)-2-(6-ethoxy-2,3-dihydro-1H-3a-aza-cyclopenta(a)inden-8-yl)-1-methyl-ethylamine for example; treating diabetes; in combination with a lipase inhibitor such as orlistat | PNLIP, LIPA, LPL | HTR2A 585/4885HTR2C 502/4885ALDH1A1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.